PER-001 demonstrated a favorable safety and tolerability profile in diabetic retinopathy and glaucoma SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical ...
Patients with vitiligo face a higher risk for diabetic retinopathy, glaucoma, AMD, and vitreous hemorrhage, per ASCRS 2026 ...
Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss remains one of its most devastating complications. Understanding how diabetes ...
Please provide your email address to receive an email when new articles are posted on . GLP-1RA use was associated with a 19% reduction in risk for glaucoma in patients with type 2 diabetes. Long-term ...
Please provide your email address to receive an email when new articles are posted on . Age-related dementia, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy and hearing ...
AUSTIN, Texas — According to the 2022 National Diabetes Statistics Report from the Centers for Disease Control and Prevention (CDC), more than 11% of the U.S. population has diabetes. With November ...
SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results